Please select the option that best describes you:

Which patients with primary, early-stage NSCLC would you utilize immunotherapy in conjunction with SBRT?  

This post refers to the recently published RCT by Chang et al., PMID 37478883 investigating lung SBRT with vs. without 4 months of nivolumab for early stage, primary NSCLC.

What subset of patients may be appropriate for this approach now?

Answer from: Radiation Oncologist at Academic Institution